Cystatin C as a predictor of mortality and cardiovascular morbidity after cardiac resynchronization therapy

Circulation Journal

Volumn 77, Issue 11, 2013, Pages 2751-2756

  Yamamoto, Toshihiko ^a   Shimano, Masayuki ^a   Inden, Yasuya ^a   Miyata, Shinjiro ^a   Inoue, Yoko ^a   Yoshida, Naoki ^d   Tsuji, Yukiomi ^c   Hirai, Makoto ^b   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^d University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

Author keywords

Biomarker; Cardiac resynchronization therapy; Cystatin C

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CREATININE; CYSTATIN C;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DEATH; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREDICTION; PREVALENCE; QRS COMPLEX; RECEIVER OPERATING CHARACTERISTIC; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

AGED; BIOLOGICAL MARKERS; CARDIAC RESYNCHRONIZATION THERAPY; CYSTATIN C; DEFIBRILLATORS, IMPLANTABLE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TIME FACTORS;

EID: 84886457736     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0179     Document Type: Article

References (39)

1. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873-880.
2. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-1853.
3. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549.
4. Momomura S, Tsutsui H, Sugawara Y, Ito M, Mitsuhashi T, Fukamizu S, et al. Clinical efficacy of cardiac resynchronization therapy with an implantable defibrillator in a Japanese population: Results of the MIRACLE-ICD outcome measured in Japanese indication (MOMIJI) study. Circ J 2012; 76: 1911-1919.
5. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, Boersma E, Simoons M, Jordaens LJ. Effects of cardiac resynchronization therapy on overall mortality and mode of death: A meta-analysis of randomized controlled trials. Eur Heart J 2006; 27: 2682-2688.
6. McAlister FA, Ezekowitz J, Hooton N, Vandermeer B, Spooner C, Dryden DM, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: A systematic review. JAMA 2007; 297: 2502-2514.
7. Hawkins NM, Petrie MC, MacDonald MR, Hogg KJ, McMurray JJ. Selecting patients for cardiac resynchronization therapy: Electrical or mechanical dyssynchrony? Eur Heart J 2006; 27: 1270-1281.
8. Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation 2008; 117: 2608-2616.
9. Fornwalt BK, Sprague WW, BeDell P, Suever JD, Gerritse B, Merlino JD, et al. Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation 2010; 121: 1985-1991.
10. Strik M, Ploux S, Vernooy K, Prinzen FW. Cardiac resynchronization therapy: Refocus on the electrical substrate. Circ J 2011; 75: 1297-1304.
11. Auricchio A, Prinzen FW. Non-responders to cardiac resynchronization therapy: The magnitude of the problem and the issues. Circ J 2011; 75: 521-527.
12. Bax JJ, Bleeker GB, Marwick TH, Molhoek SG, Boersma E, Steendijk P, et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2004; 44: 1834-1840.
13. Yu CM, Bleeker GB, Fung JW, Schalij MJ, Zhang Q, van der Wall EE, et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation 2005; 112: 1580-1586.
14. Di Biase L, Auricchio A, Sorgente A, Civello K, Klersy C, Faletra F, et al. The magnitude of reverse remodelling irrespective of aetiology predicts outcome of heart failure patients treated with cardiac resynchronization therapy. Eur Heart J 2008; 29: 2497-2505.
15. Iwano H, Yamada S, Watanabe M, Mitsuyama H, Nishino H, Yokoyama S, et al. Novel strain rate index of contractility loss caused by mechanical dyssynchrony: A predictor of response to cardiac resynchronization therapy. Circ J 2011; 75: 2167-2175.
16. Sakamaki F, Seo Y, Ishizu T, Yanaka S, Atsumi A, Yamamoto M, et al. Tissue doppler imaging dyssynchrony parameter derived from the myocardial active wall motion improves prediction of responders for cardiac resynchronization therapy. Circ J 2012; 76: 689-697.
17. Anderson LJ, Miyazaki C, Sutherland GR, Oh JK. Patient selection and echocardiographic assessment of dyssynchrony in cardiac resynchronization therapy. Circulation 2008; 117: 2009-2023.
18. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-1009.
19. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol 2006; 47: 1987-1996.
20. Lin G, Gersh BJ, Greene EL, Redfield MM, Hayes DL, Brady PA. Renal function and mortality following cardiac resynchronization therapy. Eur Heart J 2011; 32: 184-190.
21. Adelstein EC, Shalaby A, Saba S. Response to cardiac resynchronization therapy in patients with heart failure and renal insufficiency. Pacing Clin Electrophysiol 2010; 33: 850-859.
22. Shalaby A, El-Saed A, Voigt A, Albany C, Saba S. Elevated serum creatinine at baseline predicts poor outcome in patients receiving cardiac resynchronization therapy. Pacing Clin Electrophysiol 2008; 31: 575-579.
23. Fung JW, Szeto CC, Chan JY, Zhang Q, Chan HC, Yip GW, et al. Prognostic value of renal function in patients with cardiac resynchronization therapy. Int J Cardiol 2007; 122: 10-16.
24. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
25. Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type 1: Pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 2012; 60: 1031-1042.
26. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36: 29-34.
27. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001; 37: 79-83.
28. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis 2002; 40: 221-226.
29. Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of angiotensinconverting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 2011; 4: 685-691.
30. Cuculich PS, Sanchez JM, Kerzner R, Greenberg SL, Sengupta J, Chen J, et al. Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. Pacing Clin Electrophysiol 2007; 30: 207-213.
31. Eckart RE, Gula LJ, Reynolds MR, Shry EA, Maisel WH. Mortality following defibrillator implantation in patients with renal insufficiency. J Cardiovasc Electrophysiol 2006; 17: 940-943.
32. Hreybe H, Razak E, Saba S. Effect of end-stage renal failure and hemodialysis on mortality rates in implantable cardioverter-defibrillator recipients. Pacing Clin Electrophysiol 2007; 30: 1091-1095.
33. Cannizzaro LA, Piccini JP, Patel UD, Hernandez AF. Device therapy in heart failure patients with chronic kidney disease. J Am Coll Car diol 2011; 58: 889-896.
34. Van Bommel RJ, Mollema SA, Borleffs CJ, Bertini M, Ypenburg C, Marsan NA, et al. Impaired renal function is associated with echocardiographic nonresponse and poor prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2011; 57: 549-555.
35. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-470.
36. Garg AX, Papaioannou A, Ferko N, Campbell G, Clarke JA, Ray JG. Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int 2004; 65: 649-653.
37. Suzuki H, Shimano M, Yoshida Y, Inden Y, Muramatsu T, Tsuji Y, et al. Maximum derivative of left ventricular pressure predicts cardiac mortality after cardiac resynchronization therapy. Clin Cardiol 2010; 33: E18-E23.
38. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman- Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-246.
39. Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, et al. Cystatin C and estimates of renal function: Searching for a better measure of kidney function in diabetic patients. Clin Chem 2007; 53: 480-488.